Biontech Se

This study tested updated versions of the Pfizer-BioNTech COVID-19 vaccine in over 1,400 healthy people who had already received prior COVID-19 vaccines. Participants received a single booster dose of one of several new vaccine formulas designed to target newer virus variants. Th…

This study tested an experimental RNA vaccine (BNT165e) to prevent malaria in 163 healthy adults who had never had malaria. Participants received different doses of the vaccine and were later exposed to malaria in a controlled setting to see if the vaccine could protect them. The…

This early-stage study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check safety and find the right dose, while also looking for sign…

This early-stage trial tested two experimental vaccines against tuberculosis in 120 healthy adults who had never received a TB vaccine or been exposed to TB. The main goal was to check safety and find the best dose. Participants received three shots of either a vaccine or a place…

This study tested a new RNA-based vaccine (BNT166a) to prevent mpox (monkeypox). About 96 healthy adults received different doses to check safety and how well the vaccine triggers an immune response. The trial is complete, and results will help decide if the vaccine should move t…

This study tested new modified RNA vaccines that target both the flu and COVID-19. Healthy adults aged 18 and older received a single shot of either a flu vaccine, a COVID-19 vaccine, or a combination of both. The goal was to check safety and how well the body's immune system res…

This large study tested whether giving extra doses (boosters) of the Pfizer-BioNTech COVID-19 vaccine to healthy people who already had the vaccine was safe and helped prevent COVID-19. Over 16,000 people took part, and the study looked at different booster schedules and doses. T…

This study tested updated mRNA vaccines designed to protect against new SARS-CoV-2 variants (like XBB.1.5, JN.1, and KP.2). About 1,051 healthy people aged 12 and older received a single shot. Researchers monitored side effects and measured immune responses for six months to see …

This study tested a COVID-19 mRNA vaccine (BNT162b2) in 960 healthy Chinese adults aged 18 to 85. Participants received two shots, 21 days apart, and were monitored for about 13 months. The main goal was to check safety and measure the body's immune response, specifically neutral…

This early-stage trial tested a new RNA-based vaccine designed to protect against malaria. Sixty healthy adults received different doses of the vaccine or a placebo to check for safety and immune response. The study was completed and will help decide if larger trials should move …

This large study tested the safety and effectiveness of the Pfizer-BioNTech mRNA vaccine (BNT162b2) in nearly 47,000 healthy volunteers aged 12 and older. Participants received two doses of the vaccine or a placebo, and the trial showed the vaccine was highly effective at prevent…

This study tested a single combined vaccine that aims to protect against both COVID-19 and influenza. About 8,800 healthy adults received either the combo shot or separate vaccines. Researchers monitored safety and immune responses for 6 months to see if the combined approach is …

This early-stage trial tested a new RNA-based COVID-19 booster vaccine in 383 healthy adults who had already received a COVID-19 vaccine. The main goal was to see if the vaccine was safe and to find the best dose. Researchers measured side effects and immune responses after one o…

This early-stage study tested a personalized RNA vaccine designed to train the immune system to attack triple negative breast cancer cells. 42 patients received custom-made vaccines based on their tumor's unique genetic makeup. The main goal was to check safety and see if the vac…

This study tested a new cancer vaccine (BNT111) combined with an immunotherapy drug (cemiplimab) in 184 people with advanced melanoma that had stopped responding to prior treatment. The goal was to see if the combination could shrink tumors better than either treatment alone. Par…

This early-stage trial tested two experimental drugs, BNT152 and BNT153, in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers also looked for si…